Literature DB >> 2044046

5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.

M Schlumberger1, L Brugieres, C Gicquel, J P Travagli, J P Droz, C Parmentier.   

Abstract

Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP). All had a large tumor burden. Six patients had a hormone-producing tumor; mitotane treatment was given to five of them during chemotherapy for its possible antihormonal effects. Treatment could be evaluated in 13 patients. The overall response rate was 23% (95% confidence interval [CI], 5% to 54%). A complete remission, which lasted for 42 months, was achieved in one patient. Partial remissions, which lasted for 6 and 11 months, were achieved in two patients. Cardiotoxicity appeared in three patients, myelotoxicity in four, and nephrotoxicity in one. This confirms that this regimen is an active combination for the treatment of metastatic adrenal cortical carcinoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044046     DOI: 10.1002/1097-0142(19910615)67:12<2997::aid-cncr2820671211>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Current perspective in the diagnosis and treatment of adrenocortical carcinoma.

Authors:  D E Schteingart
Journal:  Rev Endocr Metab Disord       Date:  2001-08       Impact factor: 6.514

Review 2.  Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Authors:  E Baudin; S Leboulleux; A Al Ghuzlan; C Chougnet; J Young; D Deandreis; F Dumont; F Dechamps; C Caramella; P Chanson; E Lanoy; I Borget; M Schlumberger
Journal:  Horm Cancer       Date:  2011-12       Impact factor: 3.869

Review 3.  Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.

Authors:  Irina Veytsman; Lynnette Nieman; Tito Fojo
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 4.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 6.  Cytotoxic treatment of adrenocortical carcinoma.

Authors:  H Ahlman; A Khorram-Manesh; S Jansson; B Wängberg; O Nilsson; C E Jacobsson; S Lindstedt
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 7.  Adrenal cortical carcinoma.

Authors:  A P Dackiw; J E Lee; R F Gagel; D B Evans
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

Review 8.  [Drug therapy of endocrine neoplasms. Part I: Thyroid neoplasms, adrenal neoplasms and parathyroid neoplasms].

Authors:  M Schott; W A Scherbaum; J Feldkamp
Journal:  Med Klin (Munich)       Date:  2000-01-15

9.  Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane.

Authors:  P Sperone; A Berruti; G Gorzegno; P Paccotti; M Terzolo; F Porpiglia; A Angeli; L Dogliotti
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

Review 10.  [Adrenocortical carcinoma. Diagnostic work-up and treatment].

Authors:  S Johanssen; M Fassnacht; D Brix; A-C Koschker; S Hahner; H Riedmiller; B Allolio
Journal:  Urologe A       Date:  2008-02       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.